Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc. granted non-statutory stock options to two new employees under the 2022 Inducement Stock Incentive Plan. The employees received a total of 85,600 options to purchase shares of the company's common stock at $11.33 per share, with a ten-year term and vesting over four years.
03/08/2024 - 04:30 PM
CAMBRIDGE, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted the new employees an aggregate of 85,600 options to purchase shares of the company’s common stock at an exercise price of $11.33 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, March 4, 2024. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese LifeSci Advisors, LLCccalabrese@lifesciadvisors.com 917-680-5608
How many new employees were granted stock options by Fulcrum Therapeutics, Inc.?
Fulcrum Therapeutics, Inc. granted stock options to two new employees.
Under which plan did Fulcrum Therapeutics, Inc. grant the stock options?
Fulcrum Therapeutics, Inc. granted stock options under the 2022 Inducement Stock Incentive Plan.
How many options were granted to the new employees?
The new employees received a total of 85,600 options to purchase shares of the company's common stock.
At what price per share were the options granted?
The options were granted at an exercise price of $11.33 per share.
How long is the term for each option granted?
Each option has a ten-year term.
How does the vesting of the options work?
The options vest over four years, with 25% of the shares vesting on the first anniversary and the rest vesting in equal quarterly installments over the twelve subsequent quarters.
FULC Rankings
#4442 Ranked by Stock Gains
FULC Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About FULC
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng